<DOC>
	<DOCNO>NCT00376779</DOCNO>
	<brief_summary>The purpose study show immunogenicity newly formulate DTPa-HBV-IPV/Hib vaccine good immunogenicity currently license formulation vaccine . The vaccine administer primary vaccination course healthy infant 2 , 3 4 month age safety reactogenicity also assess .</brief_summary>
	<brief_title>Immunogenicity Safety DTPa-HBV-IPV/Hib Vaccine Given 2 , 3 4 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A healthy male female , include , 8 12 week age time first vaccination . Written inform consent obtain parents/guardians subject . Born normal gestation period 36 42 week . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug birth first primary vaccination dose . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration/planned administration vaccine foreseen study protocol period start 30 day administration first dose end 30 day last dose , exception human rotavirus ( HRV ) vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Evidence previous intercurrent diphtheria , tetanus , pertussis , polio , hepatitis B and/or Haemophilus influenza type b ( Hib ) vaccination disease . Hepatitis B virus ( HBV ) vaccination birth . History seizures progressive neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Finland</keyword>
	<keyword>randomize</keyword>
	<keyword>phase 2</keyword>
	<keyword>GSK Biologicals</keyword>
	<keyword>DTPa-HBV-IPV/Hib</keyword>
</DOC>